scispace - formally typeset
Search or ask a question
Journal ArticleDOI

The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia

John R. Srigley1, Brett Delahunt2, John N. Eble3, Lars Egevad4, Jonathan I. Epstein5, David J. Grignon3, Ondrej Hes6, Holger Moch7, Rodolfo Montironi, Satish K. Tickoo5, Ming Zhou8, Pedram Argani9, Anila Abraham, Adebowale J. Adeniran, Khalid Ahmed, Hikmat Al Ahmadie, Ferran Algaba, Robert W. Allan, Mahul B. Amin, Ulrika Axcrona, Marc Barry, Dilek Ertoy Baydar, Louis R. Bégin, Daniel M. Berney, Peter Bethwaite, Athanase Billis, Ruth Birbe, Stephen M. Bonsib, David G. Bostwick, Fadi Brimo, Helen P. Cathro, Ying-Bei Chen, Liang Cheng, John C. Cheville, Yong Mee Cho, Ai Ying Chuang, Cynthia Cohen, Henry Crist, Warick Delprado, Fang Ming Deng, Andrew Evans, Oluwole Fadare, Daniel A. Fajardo, Sara M. Falzarano, Samson W. Fine, Stewart Fleming, Eddie Fridman, Bungo Furusato, Masoud Ganji, Masoumeh Ghayouri, Giovanna A. Giannico, Neriman Gokden, David J. Griffiths, Nilesh S. Gupta, Omar Hameed, Michelle S. Hirsch, Jiaoti Huang, Wei Huang, Christina Hulsbergen Van De Kaa, Peter A. Humphrey, Sundus Hussein, Kenneth A. Iczkowski, Rafael E. Jimenez, Edward C. Jones, Laura Irene Jufe, James G. Kench, Masatoshi Kida, Glen Kristiansen, Lakshmi P. Kunju, Zhaoli Lane, Mathieu Latour, Claudio Lewin, Kathrine Lie, Josep Lloreta, Barbara Loftus, Antonio Lopez-Beltran, Fiona Maclean, Cristina Magi-Galluzzi, Guido Martignoni, Teresa McHale, Jesse K. McKenney, Maria Merino, Rose Miller, Hiroshi Miyamoto, Hedwig Murphy, John N. Nacey, Tipu Nazeer, Gabriella Nesi, George J. Netto, Peter W. Nichols, Marie O'Donnell, Semra Olgac, Roberto Orozco, Adeboye O. Osunkoya, Aysim Ozagari, Chin Chen Pan, Anil V. Parwani, Joanna Perry-Keene, Constantina Petraki, Maria M. Picken, Maria Pyda-Karwicka, Victor E. Reuter, Katayoon Rezaei, Nathalie Rioux-Leclercq, Brian D. Robinson, Stephen Rohan, Ruben Ronchetti, Laurie Russell, Hemamali Samaratunga, Marina Scarpelli, Ahmed Shabaik, Rajal B. Shah, Jonathan H Shanks, Steven S. Shen, Maria Shevchuk, Mathilde Sibony, Bhuvana Srinivasan, Martin Susani, Sueli Suzigan, Joan Sweet, Hiroyuki Takahashi, Pheroze Tamboli, Puay Hoon Tan, Isabel Trias, Kiril Trpkov, Larry True, Toyonori Tsuzuki, Funda Vakar-Lopez, Theo H. van der Kwast, Cheng Wang, Anne Y. Warren, Jorge L. Yao, Asli Yilmaz, Jin Zhao, Debra L. Zynger 
01 Oct 2013-The American Journal of Surgical Pathology (Lippincott Williams and Wilkins)-Vol. 37, Iss: 10, pp 1469-1489
TL;DR: The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors, with consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system.
Abstract: The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors (2004). Members of the group performed an exhaustive literature review, assessed the results of the preconference survey and participated in the consensus conference discussion and polling activities. On the basis of the above inputs, there was consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, the MiT family translocation RCCs (in particular t(6;11) RCC), and hereditary leiomyomatosis RCC syndrome-associated RCC. In addition, there are 3 rare carcinomas that were considered as emerging or provisional new entities: thyroid-like follicular RCC; succinate dehydrogenase B deficiency-associated RCC; and ALK translocation RCC. Further reports of these entities are required to better understand the nature and behavior of these highly unusual tumors. There were a number of new concepts and suggested modifications to the existing World Health Organization 2004 categories. Within the clear cell RCC group, it was agreed upon that multicystic clear cell RCC is best considered as a neoplasm of low malignant potential. There was agreement that subtyping of papillary RCC is of value and that the oncocytic variant of papillary RCC should not be considered as a distinct entity. The hybrid oncocytic chromophobe tumor, which is an indolent tumor that occurs in 3 settings, namely Birt-Hogg-Dube Syndrome, renal oncocytosis, and as a sporadic neoplasm, was placed, for the time being, within the chromophobe RCC category. Recent advances related to collecting duct carcinoma, renal medullary carcinoma, and mucinous spindle cell and tubular RCC were elucidated. Outside of the epithelial category, advances in our understanding of angiomyolipoma, including the epithelioid and epithelial cystic variants, were considered. In addition, the apparent relationship between cystic nephroma and mixed epithelial and stromal tumor was discussed, with the consensus that these tumors form a spectrum of neoplasia. Finally, it was thought that the synovial sarcoma should be removed from the mixed epithelial and mesenchymal category and placed within the sarcoma group. The new classification is to be referred to as the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia.
Citations
More filters
Journal ArticleDOI
TL;DR: The 2014 RCC guideline has been updated by a multidisciplinary panel using the highest methodological standards, and provides the best and most reliable contemporary evidence base for RCC management.

3,100 citations


Cites methods from "The International Society of Urolog..."

  • ...A revised histopathological classification was published in 2013 as the ISUP Vancouver classification of renal neoplasia [35]....

    [...]

  • ...At the ISUP conference, a simplified nuclear grading system, based only on the size and shape of nucleoli, was proposed to replace the Fuhrman grading system [35]....

    [...]

Journal ArticleDOI
TL;DR: This review summarizes the most significant differences between the newly published classification of urogenital tumours and the prior version for renal, penile, and testicular tumours.

2,024 citations


Cites background from "The International Society of Urolog..."

  • ...The Vancouver consensus conference of the International Society of Urological Pathology (ISUP) provided the foundation for much of the 2016 World Health Organization (WHO) renal tumour classification [1,2] (Fig....

    [...]

  • ...The Vancouver consensus conference has recommended diagnosing such tumours as type 2 papillary RCC for the time being [2]....

    [...]

Journal ArticleDOI
09 Mar 2017
TL;DR: An overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy are provided.
Abstract: Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy.

1,451 citations

Journal ArticleDOI
TL;DR: Several factors should be considered during counseling/management of patients with clinically localized renal masses, including general health/comorbidities, oncologic potential of the mass, pertinent functional issues and relative efficacy/potential morbidities of various management strategies.

990 citations


Cites background from "The International Society of Urolog..."

  • ...Major sub-classifications of RCC include clear cell, papillary, chromophobe, collecting duct and unclassified RCC.(37) A number of uncommon or rare subtypes exist including but not limited to acquired cystic disease-associated RCC, clear cell (tubulo) papillary, and renal medullary carcinoma, which is an aggressive variant typically seen in patients with sickle cell trait....

    [...]

  • ...34 Recent studies have been unable to confirm a survival benefit for LND for RCC. 35 If lymph node involvement is confirmed on final pathology, medical oncology consultation should be considered....

    [...]

  • ...(Moderate Recommendation; Evidence Level: Grade C) Absolute indications for nephron-sparing approaches include situations in which RN would render the patient anephric or high-risk for renal replacement therapy.1 These include patients with anatomic or functionally solitary kidney, bilateral tumors, or known familial RCC. 1 While patients with familial RCC have two functional kidneys, they are likely to experience tumor recurrence and require multiple renal interventions throughout their lifetime....

    [...]

  • ...%) of kidney cancers are renal cortical tumors known as RCC....

    [...]

  • ...7 The “classic triad” of symptoms (hematuria/flank pain/abdominal mass) are most often associated with locally advanced or metastatic RCC. Tumor Characteristics The vast majority (>90...

    [...]

Journal ArticleDOI
TL;DR: The 5-year survival rate among patients with kidney cancer increased from 57% in 1987−1989 to 74% in 2006−20121; this increase was attributable in part to a higher proportion of indolent and low-stage tumors identified using improved early-detection techniques.
Abstract: Until recently, there was a dearth of effective systemic therapies for kidney cancer. The incidence of the disease steadily increased from 1975 through 2008 and leveled off after 2008.1-3 Currently, it is among the 10 most frequently diagnosed cancers in men and women in the United States, with more than an estimated 62,000 new cases in 2016.4 The prognosis has historically been poor, with current 5-year survival rates of 74% overall, decreasing to 53% among patients with locoregional (stage III) disease and 8% among patients with metastatic disease.1,3 Kidney cancer is a disease of the middle-aged and elderly: 91% of patients receive a diagnosis at 45 years of age or older, and 48% receive a diagnosis at 65 years of age or older.1 Renal-cell carcinoma, the most common form of kidney cancer, occurs in 90% of cases and is nearly twice as common in men as in women.3 The 5-year survival rate among patients with kidney cancer increased from 57% in 1987−1989 to 74% in 2006−20121; this increase was attributable in part to a higher proportion of indolent and low-stage tumors identified using improved early-detection techniques.5 Still, one third of patients with kidney cancer present with regional or distant metastases,1 and of patients with localized renal-cell carcinoma treated with nephrectomy with curative intent, approximately one quarter have relapses in distant sites.6-8 Distant metastases occur most often in the lungs, lymph nodes, liver, bone, and brain.9 Although more than 14,000 patients die from kidney cancer each year,4 we have seen considerable progress in the systemic treatment of metastatic renal-cell carcinoma in the past 20 years.10 Researchers have achieved a better understanding of the pathogenesis of the most common type of renal-cell carcinoma, clear-cell renal-cell carcinoma. This understanding has led to new agents, expanded treatment options, and increased rates of survival.

798 citations

References
More filters
Journal ArticleDOI
TL;DR: It is shown that a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma is mapped to chromosome 1q42, and that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle.
Abstract: Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.

1,425 citations

Journal ArticleDOI
TL;DR: This paper presents the conclusions of a workshop entitled ‘Impact of Molecular Genetics on the Classification of Renal Cell Tumours’, which was held in Heidelberg in October 1996 and is applicable to routine diagnostic practice.
Abstract: This paper presents the conclusions of a workshop entitled 'Impact of Molecular Genetics on the Classification of Renal Cell Tumours', which was held in Heidelberg in October 1996. The focus on 'renal cell tumours' excludes any discussion of Wilms' tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological findings, and is applicable to routine diagnostic practice.

1,288 citations


"The International Society of Urolog..." refers background or methods in this paper

  • ...183 AML with epithelial cysts184 have 3 components: (1) epithelial cysts lined by cuboidal to hobnail cells, which label for PAX8 and PAX2 and likely represent entrapped renal tubules; (2) a compact subepithelial “cambium-like” layer of cellular, Müllerian-like AML stroma with prominent admixed chronic inflammation; and (3) muscle-predominant AML with associated dysmorphic blood vessels exterior to the cellular subepithelial stroma....

    [...]

  • ...HOCTs associated with BHD typically show 3 morphologic patterns: (1) an admixture of areas typical of RO and CHRCC; (2) scattered chromophobe cells in the background of a typical RO; and (3) large eosinophilic cells with intracytoplasmic vacuoles (Fig....

    [...]

  • ...A predictive model of 4 atypical features included: (1) Z70% atypical epithelioid cells; (2) Z2 mitotic figures per 10 hpf; (3) atypical mitotic figures; and (4) necrosis....

    [...]

  • ...There has been consensus that oncocytosis- related HOCT are distinct tumors and that they do not represent a stage of morphologic progression between RO and CHRCC.133,137,139,141,142 HOCTs associated with BHD typically show 3 morphologic patterns: (1) an admixture of areas typical of RO and CHRCC; (2) scattered chromophobe cells in the background of a typical RO; and (3) large eosinophilic cells with intracytoplasmic vacuoles (Fig....

    [...]

  • ...At the consensus conference it was agreed upon that for a diagnosis of CDC to be made a tumor should show the following features: (1) at least some of the lesion involves the medullary region; (2) there is a predominant formation of tubules; (3) a desmoplastic stromal reaction should be present; (4) cytologic features are high grade; (5) growth pattern is infiltrative; and (6) there is an absence of other typical RCC subtypes or urothelial carcinoma....

    [...]

Journal ArticleDOI
TL;DR: It is demonstrated that there are significant differences in outcome and associations with outcome for the different histologic subtypes of RCC, highlighting the need for accurate subtyping.
Abstract: Our objective was to compare cancer-specific survival and to examine associations with outcome among the histologic subtypes of renal cell carcinoma (RCC). We studied 2385 patients whose first surgery between 1970 and 2000 was a radical nephrectomy for sporadic, unilateral RCC. All RCC tumors were classified following the 1997 Union Internationale Contre le Cancer and American Joint Committee on Cancer guidelines. There were 1985 (83.2%) patients with clear cell, 270 (11.3%) with papillary, 102 (4.3%) with chromophobe, 6 (0.3%) with collecting duct, 5 (0.3%) with purely sarcomatoid RCC and no underlying histologic subtype, and 17 (0.7%) with RCC, not otherwise specified. Cancer-specific survival rates at 5 years for patients with clear cell, papillary, and chromophobe RCC were 68.9%, 87.4%, and 86.7%, respectively. Patients with clear cell RCC had a poorer prognosis compared with patients with papillary and chromophobe RCC (p <0.001). This difference in outcome was observed even after stratifying by 1997 tumor stage and nuclear grade. There was no significant difference in cancer-specific survival between patients with papillary and chromophobe RCC (p = 0.918). The 1997 TNM stage, tumor size, presence of a sarcomatoid component, and nuclear grade were significantly associated with death from clear cell, papillary, and chromophobe RCC. Histologic tumor necrosis was significantly associated with death from clear cell and chromophobe RCC, but not with death from papillary RCC. Our results demonstrate that there are significant differences in outcome and associations with outcome for the different histologic subtypes of RCC, highlighting the need for accurate subtyping.

1,012 citations

Related Papers (5)
Brett Delahunt, John C. Cheville, Guido Martignoni, Peter A. Humphrey, Cristina Magi-Galluzzi, Jesse K. McKenney, Lars Egevad, Ferran Algaba, Holger Moch, David J. Grignon, Rodolfo Montironi, John R. Srigley, John R. Srigley, Anila Abraham, Adebowale J. Adeniran, Khalid Ahmed, Hikmat Al Ahmadie, Robert W. Allan, Mahul B. Amin, Pedram Argani, Ulrika Axcrona, Marc Barry, Dilek Ertoy Baydar, Louis R. Bégin, Daniel M. Berney, Peter Bethwaite, Athanase Billis, Ruth Birbe, Stephen M. Bonsib, David G. Bostwick, Fadi Brimo, Helen P. Cathro, Ying-Bei Chen, Liang Cheng, Yong Mee Cho, Ai Ying Chuang, Cynthia Cohen, Henry Crist, Warick Delprado, Fang Ming Deng, Jonathan I. Epstein, Andrew Evans, Oluwole Fadare, Daniel A. Fajardo, Sara M. Falzarano, Samson W. Fine, Stewart Fleming, Eddie Fridman, Bungo Furusato, Masoud Ganji, Masoumeh Ghayouri, Giovanna A. Giannico, Neriman Gokden, David J. Griffiths, Nilesh S. Gupta, Omar Hameed, Ondrej Hes, Michelle S. Hirsch, Jiaoti Huang, Wei Huang, Christina Hulsbergen Van De Kaa, Sundus Hussein, Kenneth A. Iczkowski, Rafael E. Jimenez, Edward C. Jones, Laura Irene Jufe, James G. Kench, Masatoshi Kida, Glen Kristiansen, Lakshmi P. Kunju, Zhaoli Lane, Mathieu Latour, Claudio Lewin, Kathrine Lie, Josep Lloreta, Barbara Loftus, Antonio Lopez-Beltran, Fiona Maclean, Teresa McHale, Maria Merino, Rose Miller, Hiroshi Miyamoto, Hedwig Murphy, John N. Nacey, Tipu Nazeer, Gabriella Nesi, George J. Netto, Peter W. Nichols, Marie O'Donnell, Semra Olgac, Roberto Orozco, Adeboye O. Osunkoya, Aysim Ozagari, Chin Chen Pan, Anil V. Parwani, Joanna Perry-Keene, Constantina Petraki, Maria M. Picken, Maria Pyda-Karwicka, Victor E. Reuter, Katayoon Rezaei, Nathalie Rioux-Leclercq, Brian D. Robinson, Stephen Rohan, Ruben Ronchetti, Laurie Russell, Marina Scarpelli, Ahmed Shabaik, Rajal B. Shah, Jonathan H Shanks, Steven S. Shen, Maria Shevchuk, Mathilde Sibony, Bhuvana Srinivasan, Martin Susani, Sueli Suzigan, Joan Sweet, Hiroyuki Takahashi, Puay Hoon Tan, Satish K. Tickoo, Isabel Trias, Larry True, Toyonori Tsuzuki, Funda Vakar-Lopez, Theo H. van der Kwast, Cheng Wang, Anne Y. Warren, Jorge L. Yao, Asli Yilmaz, Jin Zhao, Ming Zhou, Debra L. Zynger